ProPhase Labs (PRPH) Competitors $0.33 -0.03 (-9.34%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$0.79 +0.46 (+142.26%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PRPH vs. PYXS, BYSI, SRZN, FBRX, VNRX, IGMS, IMMX, CNTX, STRO, and INKTShould you be buying ProPhase Labs stock or one of its competitors? The main competitors of ProPhase Labs include Pyxis Oncology (PYXS), BeyondSpring (BYSI), Surrozen (SRZN), Forte Biosciences (FBRX), VolitionRx (VNRX), IGM Biosciences (IGMS), Immix Biopharma (IMMX), Context Therapeutics (CNTX), Sutro Biopharma (STRO), and MiNK Therapeutics (INKT). These companies are all part of the "pharmaceutical products" industry. ProPhase Labs vs. Its Competitors Pyxis Oncology BeyondSpring Surrozen Forte Biosciences VolitionRx IGM Biosciences Immix Biopharma Context Therapeutics Sutro Biopharma MiNK Therapeutics Pyxis Oncology (NASDAQ:PYXS) and ProPhase Labs (NASDAQ:PRPH) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, earnings, institutional ownership, profitability, media sentiment and dividends. Which has higher earnings & valuation, PYXS or PRPH? ProPhase Labs has lower revenue, but higher earnings than Pyxis Oncology. Pyxis Oncology is trading at a lower price-to-earnings ratio than ProPhase Labs, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPyxis Oncology$16.15M4.22-$77.33M-$1.59-0.69ProPhase Labs$6.77M2.00-$53.36M-$1.26-0.26 Do analysts recommend PYXS or PRPH? Pyxis Oncology presently has a consensus target price of $9.00, suggesting a potential upside of 718.18%. Given Pyxis Oncology's stronger consensus rating and higher possible upside, equities analysts clearly believe Pyxis Oncology is more favorable than ProPhase Labs.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Pyxis Oncology 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80ProPhase Labs 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has more volatility and risk, PYXS or PRPH? Pyxis Oncology has a beta of 1.13, suggesting that its stock price is 13% more volatile than the S&P 500. Comparatively, ProPhase Labs has a beta of -0.48, suggesting that its stock price is 148% less volatile than the S&P 500. Is PYXS or PRPH more profitable? Pyxis Oncology's return on equity of -57.49% beat ProPhase Labs' return on equity.Company Net Margins Return on Equity Return on Assets Pyxis OncologyN/A -57.49% -45.17% ProPhase Labs N/A -184.38%-64.59% Do institutionals and insiders hold more shares of PYXS or PRPH? 39.1% of Pyxis Oncology shares are held by institutional investors. Comparatively, 9.5% of ProPhase Labs shares are held by institutional investors. 10.6% of Pyxis Oncology shares are held by company insiders. Comparatively, 9.6% of ProPhase Labs shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Does the media favor PYXS or PRPH? In the previous week, Pyxis Oncology and Pyxis Oncology both had 1 articles in the media. Pyxis Oncology's average media sentiment score of 0.76 beat ProPhase Labs' score of 0.00 indicating that Pyxis Oncology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pyxis Oncology 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ProPhase Labs 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryPyxis Oncology beats ProPhase Labs on 11 of the 14 factors compared between the two stocks. Get ProPhase Labs News Delivered to You Automatically Sign up to receive the latest news and ratings for PRPH and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PRPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PRPH vs. The Competition Export to ExcelMetricProPhase LabsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$13.55M$2.50B$5.52B$9.35BDividend YieldN/A1.79%4.74%4.14%P/E Ratio-0.268.9029.0523.78Price / Sales2.00693.47444.6497.50Price / CashN/A22.2824.4827.20Price / Book1.304.838.365.61Net Income-$53.36M$31.61M$3.25B$265.26M7 Day Performance-26.55%-4.82%-3.57%-4.34%1 Month Performance-19.68%3.12%5.10%4.11%1 Year Performance-88.83%-2.00%25.36%17.92% ProPhase Labs Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PRPHProPhase Labs0.6116 of 5 stars$0.33-9.3%N/A-88.8%$13.55M$6.77M-0.26130Gap DownPYXSPyxis Oncology2.4202 of 5 stars$1.23-2.0%$9.00+634.7%-68.1%$77.43M$16.15M-0.7760Positive NewsGap UpBYSIBeyondSpringN/A$1.92flatN/A+11.9%$77.41M$1.75M0.0080SRZNSurrozen1.8233 of 5 stars$9.31+4.0%$38.50+313.5%+43.5%$76.64M$10.65M-0.3780Upcoming EarningsGap DownFBRXForte Biosciences3.108 of 5 stars$11.63+0.3%$61.00+424.5%+45,221.6%$76.37MN/A-0.715Positive NewsVNRXVolitionRx1.4662 of 5 stars$0.73-2.6%$3.50+379.3%+0.6%$75.94M$1.31M-2.0380Gap UpIGMSIGM Biosciences4.2168 of 5 stars$1.26-0.8%$5.50+336.5%-85.0%$75.91M$2.68M-0.39190Earnings ReportHigh Trading VolumeIMMXImmix Biopharma2.6231 of 5 stars$2.72+0.4%$7.00+157.4%+23.8%$75.55MN/A-3.899Positive NewsUpcoming EarningsCNTXContext Therapeutics2.5824 of 5 stars$0.85+1.1%$5.50+547.1%-69.0%$75.44MN/A-2.747Positive NewsUpcoming EarningsSTROSutro Biopharma3.4501 of 5 stars$0.85-3.7%$6.11+616.0%-77.4%$74.93M$62.04M-0.29240News CoverageINKTMiNK Therapeutics2.4188 of 5 stars$18.71+0.8%$37.50+100.4%+68.6%$73.97MN/A-7.4230Short Interest ↑Gap Up Related Companies and Tools Related Companies PYXS Competitors BYSI Competitors SRZN Competitors FBRX Competitors VNRX Competitors IGMS Competitors IMMX Competitors CNTX Competitors STRO Competitors INKT Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PRPH) was last updated on 8/4/2025 by MarketBeat.com Staff From Our PartnersCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredWall Street Laughed. Now They're Buying.For six months, I’ve been pounding the table on a major gold miner—while Twitter pundits laughed. But now, the...Golden Portfolio | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | Sponsored[Shocking New Report] U.S. Dollar To Crash?The "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…Goldco Precious Metals | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Create New Advertiser | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredTrump’s biggest move, misreportedThe media and financial pundits are all misreading Trump’s actions. They think Trump wants to make Canada t...Porter & Company | SponsoredMarket Crash Warning: How to Protect Your Wealth Before August 12thChina tariffs hit August 12—and experts warn a market meltdown may follow. A free guide from American Alter...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ProPhase Labs, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ProPhase Labs With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
